Search results for "therapeutic strategies"

showing 7 items of 7 documents

Molecular Mechanisms of Inflammasome in Ischemic Stroke Pathogenesis.

2022

Ischemic stroke (also called cerebral ischemia) is one of the leading causes of death and severe disability worldwide. NLR inflammasomes play a crucial role in sensing cell damage in response to a harmful stimuli and modulating the inflammatory response, promoting the release of pro-inflammatory cytokines such as IL-18 and IL-1β following ischemic injury. Therefore, a neuroprotective effect is achieved by inhibiting the expression, assembly, and secretion of inflammasomes, thus limiting the extent of brain detriment and neurological sequelae. This review aims to illustrate the molecular characteristics, expression levels, and assembly of NLRP3 (nucleotide-binding oligomerization domain-like…

NLRC4Settore MED/09 - Medicina InternaNLRP2 inflammasomeDrug Discoveryischemic strokeNLRP1 inflammasomePharmaceutical ScienceMolecular Medicinetherapeutic strategiesNLRP3 inflammasomeneuroinflammationPharmaceuticals (Basel, Switzerland)
researchProduct

An immunologist's guide to immunosenescence and its treatment

2022

Abstract Introduction: Aging causes several changes in the immune system, although immune aging is strongly influenced by individual immunological history, as well as genetic and environmental factors leading to inter-individual variability. Areas covered: We focused on the biological and clinical meaning of immunosenescence. SARS-CoV-2 and Yellow Fever vaccine have demonstrated the clinical relevance of immunosenescence, while inconsistent results, obtained from longitudinal studies aimed at looking for immune risk phenotypes, have revealed that immunosenescence is highly context-dependent. Large projects allowed the delineation of the drivers of immune system variance, including genetic a…

immunosenescenceSettore MED/04 - Patologia GeneraleAgingnaïve cellsSARS-CoV-2ImmunologyCOVID-19TEMRAinflamm-agingImmune SystemTEMImmunology and AllergyHumanstherapeutic strategiesHCMV
researchProduct

Cellular Senescence in Age-Related Diseases: Molecular Bases and Therapeutic Interventions

2022

Due to the increase in life expectancy, the aging population around the globe has been growing significantly and is estimated to triple by 2050 [...]

Settore BIO/10 - Biochimicatherapeutic strategies antioxidants phytochemicals metabolism inflammagingGeneral MedicineCellular SenescenceCells
researchProduct

TOWARDS COLORECTAL CANCER STEM CELLS TARGETING: INVESTIGATING GENETIC AND EPIGENETIC LANDSCAPE

2022

Colorectal cancer Cancer stem cells Epigenetic alterations Therapeutic strategies
researchProduct

The regulation of efferocytosis signaling pathways and adipose tissue homeostasis in physiological conditions and obesity: Current understanding and …

2022

Obesity is associated with changes in the resolution of acute inflammation that contribute to the clinical complications. The exact mechanisms underlying unresolved inflammation in obesity are not fully understood. Adipocyte death leads to pro-inflammatory adipose tissue macrophages, stimulating additional adipocyte apoptosis. Thus, a complex and tightly regulated process to inhibit inflammation and maintain homeostasis after adipocyte apoptosis is needed to maintain health. In normal condition, a specialized phagocytic process (efferocytosis) performs this function, clearing necrotic and apoptotic cells (ACs) and controlling inflammation. For efficient and continued efferocytosis, phagocyt…

InflammationAdipose TissueEndocrinology Diabetes and MetabolismPublic Health Environmental and Occupational HealthHomeostasisHumansObesityadipose tissue homeostasis clearance of apoptotic adipocytes continual efferocytosis high fat diet insulin resistance metabolic connections metabolic inflammation therapeutic strategiesSignal TransductionObesity Reviews
researchProduct

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

2014

Abstract: Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients harbouring activating EGFR mutations. However, even in long-lasting responses, resistance to EGFR TKIs invariably occurs. Areas covered: This review examines resistance mechanisms to EGFR TKI treatment, which mainly arise from secondary EGFR mutations. Other resistance-inducing processes include mesenchymal-epithelial transition factor (MET) amplification, epithelial-mesenchymal transformation, phenotypic change from NSCLC to small-cell lung carcinoma, and modifications in parallel signalling pathways. Current…

Lung NeoplasmsSettore MED/06 - Oncologia MedicaAfatinibNovel therapeutic strategiesLapatinibmedicine.disease_causeNSCLCT790Mchemistry.chemical_compoundErbB ReceptorsCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansRadiology Nuclear Medicine and imagingEpidermal growth factor receptorProtein Kinase InhibitorsEGFR inhibitorsbiologybusiness.industryEGFR mutations; TKI inhibitors resistance; NSCLC; New drugs; Novel therapeutic strategiesGeneral MedicineNew drugEGFR mutationsCombined Modality TherapyDacomitinibrespiratory tract diseasesErbB ReceptorsNew drugsOncologychemistryDrug Resistance NeoplasmCancer researchbiology.proteinKRASHuman medicineEGFR mutationbusinessmedicine.drugTKI inhibitors resistanceCancer Treatment Reviews
researchProduct

Treatment of heart failure with preserved ejection fraction.

2018

Heart failure, in its diverse forms based on the value of the ejection fraction, is associated to high mortality and the frequent need for hospitalization, with a consequent heavy burden on healthcare resources. For an appropriate treatment of heart failure with preserved ejection fraction (HFpEF), there are no specific drugs effective for this condition. Those indicated in HF with reduced EF (HFrEF) are of more benefit in that form of HF, according to the guidelines of the European Society of Cardiology of 2016: ACE-inhibitors, beta-blockers, anti-aldosterones are all indicated with a class of recommendation/level of evidence IA; therapy with loop diuretics is indicated in the case of clin…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyEjection fractionSettore MED/09 - Medicina Internalcsh:Medicineheart failuretherapeutic strategies.Hospitalization rateInternal medicineMedicineAerobic exerciseguidelinesEjection fraction; comorbidity; guidelines; heart failure; therapeutic strategies.Ejection fractionbusiness.industryHigh mortalitylcsh:REvidence-based medicinemedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolarecomorbidityHeart failureCardiologyCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessguidelineMonaldi archives for chest disease = Archivio Monaldi per le malattie del torace
researchProduct